Literature DB >> 24467609

Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice.

S Zoppi1, J L Madrigal, J R Caso, M S García-Gutiérrez, J Manzanares, J C Leza, B García-Bueno.   

Abstract

BACKGROUND AND
PURPOSE: Stress exposure produces excitotoxicity and neuroinflammation, contributing to the cellular damage observed in stress-related neuropathologies. The endocannabinoids provide a homeostatic system, present in stress-responsive neural circuits. Here, we have assessed the possible regulatory role of cannabinoid CB2 receptors in stress-induced excitotoxicity and neuroinflammation. EXPERIMENTAL APPROACH: We used wild type (WT), transgenic overexpressing CB2 receptors (CB2xP) and CB2 receptor knockout (CB2-KO) mice exposed to immobilization and acoustic stress (2 h·day(-1) for 4 days). The CB2 receptor agonist JWH-133 was administered daily (2 mg·kg(-1), i.p.) to WT and CB2-KO animals. Glutamate uptake was measured in synaptosomes from frontal cortex; Western blots and RT-PCR were used to measure proinflammatory cytokines, enzymes and mediators in homogenates of frontal cortex. KEY
RESULTS: Increased plasma corticosterone induced by stress was not modified by manipulating CB2 receptors. JWH-133 treatment or overexpression of CB2 receptors increased control levels of glutamate uptake, which were reduced by stress back to control levels. JWH-133 prevented the stress-induced increase in proinflammatory cytokines (TNF-α and CCL2), in NF-κB, and in NOS-2 and COX-2 and in the consequent cellular oxidative and nitrosative damage (lipid peroxidation). CB2xP mice exhibited anti-inflammatory or neuroprotective actions similar to those in JWH-133 pretreated animals. Conversely, lack of CB2 receptors (CB2-KO mice) exacerbated stress-induced neuroinflammatory responses and confirmed that effects of JWH-133 were mediated through CB2 receptors. CONCLUSIONS AND IMPLICATIONS: Pharmacological manipulation of CB2 receptors is a potential therapeutic strategy for the treatment of stress-related pathologies with a neuroinflammatory component, such as depression.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  CB2 receptor; CB2xP mice; JWH-133; brain frontal cortex; excitotoxicity; neuroinflammation; stress

Mesh:

Substances:

Year:  2014        PMID: 24467609      PMCID: PMC4243857          DOI: 10.1111/bph.12607

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  62 in total

Review 1.  Immune system to brain signaling: neuropsychopharmacological implications.

Authors:  Lucile Capuron; Andrew H Miller
Journal:  Pharmacol Ther       Date:  2011-02-17       Impact factor: 12.310

Review 2.  CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity.

Authors:  Emmanuel S Onaivi; Hiroki Ishiguro; Shanzhi Gu; Qing-Rong Liu
Journal:  J Psychopharmacol       Date:  2011-03-29       Impact factor: 4.153

3.  Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine.

Authors:  Alexander Ternianov; José M Pérez-Ortiz; María E Solesio; María S García-Gutiérrez; Antonio Ortega-Álvaro; Francisco Navarrete; Carlos Leiva; María F Galindo; Jorge Manzanares
Journal:  Neurobiol Aging       Date:  2010-10-27       Impact factor: 4.673

4.  Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice.

Authors:  María S García-Gutiérrez; Jorge Manzanares
Journal:  J Psychopharmacol       Date:  2010-09-13       Impact factor: 4.153

5.  Is unpredictable chronic mild stress (UCMS) a reliable model to study depression-induced neuroinflammation?

Authors:  Rai Khalid Farooq; Elsa Isingrini; Arnaud Tanti; Anne-Marie Le Guisquet; Nicolas Arlicot; Frederic Minier; Samuel Leman; Sylvie Chalon; Catherine Belzung; Vincent Camus
Journal:  Behav Brain Res       Date:  2012-03-20       Impact factor: 3.332

Review 6.  Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?

Authors:  Karen Wager-Smith; Athina Markou
Journal:  Neurosci Biobehav Rev       Date:  2010-09-29       Impact factor: 8.989

7.  Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.

Authors:  Sabina Adhikary; Hongbo Li; Joshua Heller; Mario Skarica; Ming Zhang; Doina Ganea; Ronald F Tuma
Journal:  J Neurotrauma       Date:  2011-10-04       Impact factor: 5.269

8.  Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection.

Authors:  Juan G Zarruk; David Fernández-López; Isaac García-Yébenes; María S García-Gutiérrez; José Vivancos; Florentino Nombela; Magdalena Torres; María C Burguete; Jorge Manzanares; Ignacio Lizasoain; María A Moro
Journal:  Stroke       Date:  2011-10-20       Impact factor: 7.914

9.  Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.

Authors:  Antonio Ortega-Alvaro; Auxiliadora Aracil-Fernández; María S García-Gutiérrez; Francisco Navarrete; Jorge Manzanares
Journal:  Neuropsychopharmacology       Date:  2011-03-23       Impact factor: 7.853

10.  Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.

Authors:  Ana María Martín-Moreno; Begoña Brera; Carlos Spuch; Eva Carro; Luis García-García; Mercedes Delgado; Miguel A Pozo; Nadia G Innamorato; Antonio Cuadrado; María L de Ceballos
Journal:  J Neuroinflammation       Date:  2012-01-16       Impact factor: 8.322

View more
  31 in total

Review 1.  G protein-coupled receptors in acquired epilepsy: Druggability and translatability.

Authors:  Ying Yu; Davis T Nguyen; Jianxiong Jiang
Journal:  Prog Neurobiol       Date:  2019-08-24       Impact factor: 11.685

Review 2.  Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder.

Authors:  Matthew N Hill; Patrizia Campolongo; Rachel Yehuda; Sachin Patel
Journal:  Neuropsychopharmacology       Date:  2017-07-26       Impact factor: 7.853

3.  Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice.

Authors:  Amaya Austrich-Olivares; María Salud García-Gutiérrez; Lucía Illescas; Ani Gasparyan; Jorge Manzanares
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

4.  Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation.

Authors:  Lucile Vincent; Derek Vang; Julia Nguyen; Barbara Benson; Jianxun Lei; Kalpna Gupta
Journal:  Haematologica       Date:  2015-12-24       Impact factor: 9.941

5.  Cannabinoid receptor 1/2 double-knockout mice develop epilepsy.

Authors:  Shane Rowley; Xiaofei Sun; Isabel V Lima; Alexandra Tavenier; Antonio Carlos Pinheiro de Oliveira; Sudhansu K Dey; Steve C Danzer
Journal:  Epilepsia       Date:  2017-11-03       Impact factor: 5.864

6.  Reduced cannabinoid 2 receptor activity increases susceptibility to induced seizures in mice.

Authors:  Lindsey Shapiro; Jennifer C Wong; Andrew Escayg
Journal:  Epilepsia       Date:  2019-11-22       Impact factor: 5.864

Review 7.  Sex differences and the endocannabinoid system in pain.

Authors:  Henry L Blanton; Robert C Barnes; Melissa C McHann; Joshua A Bilbrey; Jenny L Wilkerson; Josée Guindon
Journal:  Pharmacol Biochem Behav       Date:  2021-01-12       Impact factor: 3.533

Review 8.  Emerging Role of Phospholipase-Derived Cleavage Products in Regulating Eosinophil Activity: Focus on Lysophospholipids, Polyunsaturated Fatty Acids and Eicosanoids.

Authors:  Eva Knuplez; Eva Maria Sturm; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

9.  Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Authors:  Chaela Presley; Ammaar Abidi; Satyendra Suryawanshi; Suni Mustafa; Bernd Meibohm; Bob M Moore
Journal:  Pharmacol Res Perspect       Date:  2015-07-06

Review 10.  High Times for Painful Blues: The Endocannabinoid System in Pain-Depression Comorbidity.

Authors:  Marie Fitzgibbon; David P Finn; Michelle Roche
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-05       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.